INS and type 1 diabetes mellitus: The single research study from the US examining patient perspectives about a theoretical future switch to a biosimilar insulin found that only 5% of those with type 1 diabetes indicated that they would definitely not use a biosimilar, with a further 15% stating that they would be unlikely to use one [39].